73 results about "Pseudomonas aeruginosa Infections" patented technology

Method and apparatus for using computer controlled, fiber-coupled laser delivery of treatment specific wavelength, intensity and duration of UV irradiation to control bacterial, fungal, viral and mold infections in bodily cavities, fluids and external applications. The method of treatment is focused on DNA breakdown beyond repair by natural DNA repair mechanisms of the pathogen, with less than damaging doses to tissues being treated, thus avoiding mutagenicity and carcinogenicity. The minimal intensity and duration and exposure area of any given surface of tissue to be treated is to be pre-determined by tissue and pathogen testing to optimize the therapeutic ratio. External applications include specifically Trichophyton Rubrum (toenail fungus) through the nail and Pseudomonas Aeruginosa infections in burns and elsewhere.

Improved antibodies are provided selected from human, dual-specific, chimeric or humanized antibodies, wherein said human chimeric and humanized antibodies specifically bind to flagellin type A or type B of P. aeruginosa, and said dual-specific antibodies specifically binds to flagella type A and type B of Pseudomonas aeruginosa, and said antibodies are protective against infection caused by P. aeruginosa. These antibodies as well as pharmaceutical composition comprising them are useful for the treatment of indications caused by P. aeruginosa infection.

The present invention provides improved pharmaceutical compositions and methods of treating or preventing development of bacteremia associated with Pseudomonas aeruginosa infections, where the method comprises administering an antibiotic and an anti-PcrV antibody.

The present invention relates to a pseudomonas aeruginosa phage and an application thereof, and particularly discloses the phage capable of entering blood and the application thereof. The phage singlebody is the pseudomonas aeruginosa phage with a Latin name P. Aeruginosaphage, and named as ASP11, and has a broad-spectrum bactericidal ability against pseudomonas aeruginosa. The phage ASP11 is preserved in China General Microbiological Culture Collection Center, a preservation date is September 26, 2018 and a preservation number is CGMCC NO.16395. Both in vivo and in vitro tests show that thephage has a strong cleavage effect on the pseudomonas aeruginosa and provides an effective method for prevention and treatment of pseudomonas aeruginosa infected diseases.

The invention belongs to the technical field of preparing compounds, and relates to a compound separated and extracted from marine penicillium and application thereof. The compound is used for preventing and treating in-vitra and in-vivo pseudomonas aeruginosa infection of people or animals, and the chemical formula of the compound which is obtained by fermenting the marine penicillium and has the effect of inhibiting quorum sensing of pseudomonas aeruginosa is 4,6-dimethyl-7-[(1R,2E,4aS,7R,8R,8aR)-1,2.4a,5,6,7,8,8a-octahydro-7-hydroxyl-2-(3-hydroxyl-2-oxygen-propylene)-3,6,8-trimethyl-1-naphthyl]-,(2E,4E,6E)-heptantriene acid, and the molecular formula of the compound is C25H34O5; the compound does not inhibit the growth of the wild type pseudomonas aeruginosa; the quorum-sensing inhibition effect of the compound is concentration-dependent, and is gradually strengthened with the increase of the concentration; virulence factors controlled by the quorum sensing of the pseudomonas aeruginosa can be inhibited; and the compound also has the advantages of readily available raw materials, simple and easily controlled preparation process, obvious sensing inhibition effect and prominent social benefits.

The invention provides a pCasPA/pACRISPR dual-plasmid system. The pCasPA/pACRISPR dual-plasmid system is characterized by comprising at least one of a pCasPA plasmid and a pACRISPR plasmid, the pCasPAplasmid can express Cas9 protein and a lambda-Red recombinant system, and the pACRISPR plasmid can express sgRNA. The pCasPA/pACRISPR dual-plasmid system can efficiently and rapidly knock out the genes of various strains of pseudomonas aeruginosa, efficiently and rapidly conducts gene insertion on the genomes of various strains of pseudomonas aeruginosa. The technology has the broad application prospect on the aspects such as the treatment of pseudomonas aeruginosa infection, drug target discovery, drug development and physiological research of the pseudomonas aeruginosa.

The invention relates to a method for establishing a pseudomonas aeruginosa infectious pneumonia animal model. The method comprises the following steps: 1) deeply anesthetizing a mouse by adopting isoflurane; and 2) dripping nose of the mouse with pseudomonas aeruginosa, so that a pseudomonas aeruginosa infectious pneumonia model is established. The method provided by the invention has the advantages that the mouse can be effectively infected, and the pseudomonas aeruginosa pneumonia model is successfully established; and the mouse model after infection is stable and can be applied to evaluation of vaccines and research of protective mechanisms.

The invention discloses a tricyclic quinolone derivative or its salt and hydrate with a novel structure and a non-basic substituent substituted C10 peripheral group. Activity determination of the compound by various strains proves that the compound has antibacterial activity on a variety of sensitive strains and resistant strains, can be used for treatment of infection diseases caused by Gram negative and positive bacteria, and is especially suitable for treatment of methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa infection.

The present invention is drawn to conjugates and vaccine compositions comprising a Pseudomonas flagellin or an antigenic fragment or derivative thereof linked to one or more Klebsiella surface polysaccharide antigens, such as Klebsiella pneumoniae O5 polysaccharide from serovars O1, O2a, O2a,c, O3, O4, O5, O7, O8 and 012. The present invention also provides serovar reagent strains to produce the conjugates and vaccine compositions and methods of inducing an immune response with the conjugates and vaccine compositions.

An object is to provide: a protein antigen or a peptide antigen usable as a vaccine composition which has an ability to practically prevent or treat a Pseudomonas aeruginosa infection, and which can cope with the diversity of clinical isolates derived from patients with a Pseudomonas aeruginosa infection; and an antibody directed against the antigen. The present invention provides a protein antigen or a peptide antigen and an antibody directed against these, which are for use in diagnosis, prevention, or treatment of a disease associated with Pseudomonas aeruginosa. According to the present invention, a protein or a peptide derived from a Pseudomonas aeruginosa-outer membrane protein PA4710, and an antibody directed against these are provided, which are for use in diagnosis, prevention, or treatment of a disease associated with Pseudomonas aeruginosa.

The invention discloses a pseudomonas aeruginosa OprF-VP22 gene, the application of the gene for making vaccines for controlling pseudomonas aeruginosa infection, and a pseudomonas aeruginosa DNA vaccine containing the gene.

The invention discloses application of 2,6-bis(2-benzimidazolyl) pyridine in preparation of a carbapenem-resistant pseudomonas aeruginosa infection drug. Through circular dichroism, fluorescent real-time quantitative PCR and other methods, it is found that 2, 6-bis (2-benzimidazolyl) pyridine can form a G-quadruplex structure with a core sequence of a MexA gene in pseudomonas aeruginosa, thereby inhibiting expression of the MexA gene. A susceptibility testing verifies that 2, 6-bis (2-benzimidazolyl) pyridine can reduce the drug resistance of carbapenem-resistant pseudomonas aeruginosa to meropenem. When the usage amount of the 2, 6-bis (2-benzimidazolyl) pyridine is 5 <mu>M, the minimum inhibitory concentration of the carbapenem-resistant pseudomonas aeruginosa strain can be reduced to 2<mu> g/ml, and the effect of treating carbapenem-resistant pseudomonas aeruginosa infection by using meropenem is achieved.

Disclosed herein are mono and bispecific DNA antibodies (DMAbs) targeting Pseudomonas aeruginosa. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering theDMAbs to the subject. The disclosure also provides a method of preventing and/or treating Pseudomonas aeruginosa infection in a subject using said composition and method of generation.

The invention provides a fusion protein for preventing pseudomonas aeruginosa infection. The fusion protei comprises a first peptide fragment, a second peptide fragment and a third peptide fragment which are linearly connected and combined; the amino acid sequence of the first peptide fragment is SEQ ID NO:94; the amino acid sequence of the second peptide fragment is SEQ ID NO:95; and the amino acid sequence of the third peptide fragment is SEQ ID NO: 96. The invention further provides a recombinant gene for encoding the fusion protein and application of the fusion protein in preventing the pseudomonas aeruginosa infection. The fusion protein disclosed by the invention can effectively prevent infection of various serotypes of pseudomonas aeruginosa.

Proteins derived from Pseudomonas aeruginosa are antigenic and are of use in the treatment, prophylaxis and diagnosis of P. aeruginosa infection.